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Failure of insulin to elicit an increase in glucose uptake and metabolism in target tissues such as skeletal muscle is a major characteristic of
non-insulin dependent type 2 diabetes mellitus. A strong correlation between intramyocellular triacylglycerol concentrations and the severity of
insulin resistance has been found and led to the assumption that lipid oversupply to skeletal muscle contributes to reduced insulin action. However,
the molecular mechanism that links intramyocellular lipid content with the generation of muscle insulin resistance is still unclear. It appears
unlikely that the neutral lipid metabolite triacylglycerol directly impairs insulin action. Hence it is believed that intermediates in fatty acid
metabolism, such as fatty acyl-CoA, ceramides or diacylglycerol (DAG) link fat deposition in the muscle to compromised insulin signaling. DAG
is identified as a potential mediator of lipid-induced insulin resistance, as increased DAG levels are associated with protein kinase C activation and
a reduction in both insulin-stimulated IRS-1 tyrosine phosphorylation and PI3 kinase activity.
As DAG is an intermediate in the synthesis of triacylglycerol from fatty acids and glycerol, its level can be lowered by either improving the
oxidation of cellular fatty acids or by accelerating the incorporation of fatty acids into triacylglycerol.
This review discusses the evidence that implicates DAG being central in the development of muscular insulin resistance. Furthermore, we will
discuss if and howmodulation of skeletal muscle DAG levels could function as a possible therapeutic target for the treatment of type 2 diabetes mellitus.
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receptor substrate-1; PI3K, phosphatidylinositol 3 kinase; PKC, protein kinase C;
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During the past decades, the prevalence of obesity in children
and adults has increased enormously. This is a major health issue
at the moment, because the incidence rate of obesity is currently
reaching epidemic proportions and given the current trend there
are no signs that it will decrease. Obesity is a condition char-
acterized by excess body fat and is defined with a body mass
index (in kg/m2) ≥30. Currently, 30% of American adults are
classified as obese and 1 out of every 6 children is overweight
according to the National Health and Nutrition Examination
Survey [1]. Obesity is clearly recognized as a deleterious con-
dition and predisposes individuals to a range of health com-
plications including: insulin resistance [2], type 2 diabetes [2],
hypertension, cardiac failure, and atherosclerosis, which accounts
for a high percentage of the current health care costs [3–6].
Although the association between obesity and insulin
resistance is clearly shown in epidemiologic literature, the path-
ophysiology of obesity and insulin resistance needs to be further
243S. Timmers et al. / Physiology & Behavior 94 (2008) 242–251elucidated. Insulin resistance is characterized by the reduced
ability of the pancreatic hormone insulin to promote peripheral
glucose disposal and suppress hepatic glucose output. Skeletal
muscle is considered as one of the primary tissues in glucose
homeostasis, because it accounts for 75–80% of whole body
insulin-stimulated glucose uptake [7,8]. Therefore, skeletal
muscle insulin resistance is a major determinant of hyperglyce-
mia and type 2 diabetes mellitus. Skeletal muscle insulin resis-
tance has been associated with the accumulation of total body fat
[9]. However, an even stronger association has been shown
between intramyocellular fat storage and insulin resistance in
animals [10,11] and humans [12,13]. This suggests that aberrant
storage of lipids or lipid intermediates in skeletal muscle con-
tributes to the development of insulin resistance [14].
The aim of this review is to discuss the association between
skeletal muscle insulin resistance and ectopic lipid accumula-
tion. First we will discuss the normal insulin signalling cascade
and the interference of ectopic lipids. Next, the role of the
different lipid intermediates in the development of muscular
insulin resistance will be highlighted, with a focus on DAG.
2. Insulin signalling pathways promoting glucose uptake
Insulin promotes the uptake of glucose from the plasma into
skeletal muscle (Fig. 1). The insulin receptor (IR) is an α2β2
heterodimeric transmembrane protein that possesses intrinsic
protein tyrosine kinase activity. After binding of insulin to the
extracellular domain of the α subunit, the receptor undergoes
conformational changes that result in autophosphorylation of
specific tyrosine residues in the cytoplasmic domain of the β
subunit. Autophosphorylation of tyrosine residues stimulates the
catalytic activity of receptor tyrosine kinase and creates recruit-
ment sites for insulin receptor substrate proteins, such as insulin
receptor substrate-1 (IRS-1) [15–17]. Phosphatidyl inositol 3-Fig. 1. Pathway of insulin-stimulated glucose uptake. Binding of insulin to the IR activ
PKB and aPKC. Activation of Akt and aPKC results in the translocation of GLUT4 v
acids enter the muscle cell and are either oxidized or stored as TAG. Increased fatty a
DAG, which could interfere with normal insulin signalling by activation of nPKCs, s
ultimately reducing GLUT4 translocation. IR, insulin receptor; IRS1, insulin recep
dependent kinase; Akt/PKB, Protein kinase B; aPKC, atypical protein kinase C; LCAkinase (PI3K) is a target of IRS proteins that phosphorylates
phosphatidyl inositol 4,5-biphosphate (PIP2) to form phosphati-
dyl inositol 3,4,5-triphosphate (PIP3), which in turn activates
phosphatidyl inositol-dependent kinase1 (PDK1). This Ser/Thr
kinase then activates protein kinase B (PKB or Akt) and the
atypical protein kinase C (PKC) isozymes PKCζ and PKCι/λ
[18]. Both Akt and the atypical PKCs have been implicated in the
translocation of the glucose transporter 4 (GLUT4) from the
cytosol to the plasma membrane, which mediates glucose uptake.
3. Lipid-induced insulin resistance in skeletal muscle
In the past 15 years, evidence has accumulated that increased
plasma free fatty acid (FFA) levels are associated with insulin
resistance [19–21]. Indeed, most insulin-resistant obese people
have elevated plasma FFA levels and acute elevations of plasma
FFA in diabetic or non-diabetic individuals induces insulin
resistance in a dose-dependent way [22–24]. Moreover, low-
ering plasma FFA levels by Acipimox a derivate of nicotinic
acid, which inhibits lipolysis, normalized insulin sensitivity in
obese and non-diabetic subjects, and significantly improved it
in obese diabetic patients [25]. In addition, treatment of high-fat
fed mice with acipimox lowered FFAs in the plasma and sig-
nificantly improved insulin sensitivity [26].
Several studies have aimed to elucidate the role of elevated
FFA levels in the onset of insulin resistance. Diet intervention
studies in rodents showed that insulin resistance develops after a
few weeks of high-fat feeding and is associated with the accu-
mulation of intramuscular triacylglycerol (IMTG) [10,27–30].
Another frequently used model in the literature to investigate the
role of FFA in the onset of insulin resistance is the infusion of a
lipid emulsion to increase the level of plasma fatty acids before
and during a hyperinsulinemic euglycemic clamp. Elevating FFA
levels by means of lipid infusion in humans, decreased insulin-ates PI3K through IRS1. Downstream of PI3K, PDKmediates activation of Akt/
esicles from the cytosol to the membrane, facilitating glucose uptake. Also, fatty
cid delivery to the cell might lead to accumulation of LCACoAs, ceramides and
erine/threonine phosphorylation of IR/IRS1, and impairing Akt phosphorylation
tor substrate 1; PI3K, phosphatidylinositol 3 kinase; PDK, phosphoinositide-
CoA, long-chain acyl-CoA; DAG, diacylglycerol; nPKC, novel protein kinase.
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evidence that FFA interfere with insulin action [22,31,32]. In-
terestingly, insulin resistance developed only 2–4 h after an acute
increase in the plasma FFA concentration and it takes an equally
long time to disappear after plasma FFA levels have returned to
basal levels. From these observations, it can be concluded that the
insulin desensitizing effect is not due to circulating fatty acids. It
has therefore been suggested that fatty acids first need to accu-
mulate in skeletal muscle before they can interfere with insulin
signalling [33].
Indeed, ectopic storage of lipids as IMTG might play an
important role in the onset of insulin resistance. This hypothesis is
supported by experiments with lipodystrophic mice and humans.
Lipodystrophy is a disorder characterized by the partial or com-
plete loss of adipose tissue. Excess calorie ingestion in these mice
or humans leads to high levels of ectopic lipid accumulation with
decreased insulin sensitivity as a result. Interestingly, Gavrilova et
al. [34] and Kim et al. [35] showed that this ectopic lipid
deposition could be reduced by transplanting adipose tissue from
wild-type mice into A-ZIP/F-1 mice, which have a severe form of
lipoatrophic diabetes. Transplantation of wild-type fat reversed
hyperglycemia, lowered insulin levels, and improved muscle
insulin sensitivity, together with a reduction in ectopic fat storage.
These studies suggest that not only lowering of ectopic fat depots
but also adipose tissue secretory proteins may be important for
normal glucose and lipid homeostasis. In that respect, treatment of
lipodystrophic mice and humans with the anorexogenic adipo-
cyte-derived hormone leptin [36,37] resulted in a remarkable
improvement in insulin-stimulated liver and muscle glucose
metabolism together with lowering fat stores [38].
Also, treatment of obese Zucker rats with Thiazolidinediones
(TZD) support the hypothesis that muscular fat accumulation
leads to insulin resistance. TZDs activate peroxisome proliferator
γ (PPARγ) receptors in adipocytes, and promote adipocyte dif-
ferentiation, which results in the redistribution of fat from liver
and muscle into adipocytes and as a consequence an overall
improvement in insulin sensitivity [39]. However, recently it has
been shown that treatment of type 2 diabetics with the PPARγ
agonist Pioglitazone may improve insulin sensitivity both by
affecting serum adipokine concentrations and by reducing the
intracellular triglyceride content of liver and skeletal muscle [40].
4. IMTG versus lipid intermediates
Although many studies associate IMTG storage with insulin
resistance, the causality is not entirely validated. First of all,
endurance training in obese humans improves skeletal muscle
insulin resistance with little or no changes in IMTG concentra-
tions [41,42]. Furthermore, Phillips et al. [43] have shown that
endurance training in healthy volunteers progressively increased
IMTG deposits, while simultaneously improving insulin sensi-
tivity. In line with this, our group has recently shown that a short-
term endurance training program increased IMTG content before
insulin sensitivity was improved [44]. Another remarkable find-
ing is that elite endurance trained athletes are amongst the most
insulin-sensitive people and yet exhibit extremely high IMTG
concentrations [45]. This metabolic paradox suggests that it isunlikely that the IMTG pool is responsible for the reduced insulin
action. Nowadays, this paradox is explained by the accumulation
of lipid intermediates such as fatty acyl-CoA, ceramides and
diacylglycerol, which might suppress insulin sensitivity [46]
(Fig. 1).
4.1. Long-chain acyl-CoAs
Long-chain acyl-CoAs (LCACoAs) are the metabolically
activated form of intracellular fatty acids produced by the action
of the enzyme Acyl-CoA synthetase. LCACoAs are transported
into the mitochondria for Beta-oxidation or used as an
intermediate in the production of other lipid species. Increased
uptake of FFAs or breakdown of IMTG stores could lead to high
levels of intracellular LCACoAs. This formof lipidmay influence
energy metabolism acutely by changing substrate availability or
by altering key enzyme activities via allosteric regulation. In-
creased muscular LCACoA levels have been associated with
insulin resistance based on numerous animal and human studies
in which the LCACoA levels are modulated by different dietary
interventions or acutely via lipid infusion [27,47–49]. In addition,
incubation of isolated rat soleus muscle strips with fatty acids
reduced glucose uptake in a manner that correlated with the
accumulation of LCACoA [50]. Moreover, interventions such as
a single exercise bout or overnight fasting decreased the
intramuscular LCACoA content in 3 week high-fat fed rats and
increased insulin-stimulated glucose uptake into skeletal muscle
[51]. Several mechanisms have been postulated that link
LCACoAs with decreased insulin signalling. LCACoAs were
shown to modulate enzyme activity of hexokinase in muscle and
therefore directly regulate glucose influx. In liver, LCACoAs
have been shown to modulate directly or indirectly the activity of
key metabolic enzymes such as acyl-coA synthase, glucokinase,
glucose-6-phosphatase, hormone sensitive lipase or AMP kinase
[52]. Alternatively, LCACoAs might interfere with insulin
signalling by activation of PKC isozymes [53,54]. However,
despite the afore-mentioned evidence, LCACoA could also be a
marker of increased muscular ceramide or DAG levels, which are
associatedwith insulin resistance, as elevated LCACoA levels are
often accompanied by elevated levels of the latter.
4.2. Ceramides
Ceramides can be generated from two fatty acids and serine via
4 enzymatic steps. They have a function as signalling molecule in
several important physiological events including inhibition of cell
division and stimulation of apoptosis. The synthesis of ceramides
largely depends on the availability of long-chain saturated fatty
acids, which together with serine are the rate limiting substrates in
the de novo ceramide synthesis by serine palmitoyltransferase
(SPT) [55]. SPT is specific for saturated FFAs, in contrast to
incorporation of the second FFA in ceramides, which can orig-
inate from saturated or unsaturated FFAs [55]. Ceramides are also
proposed to play a role in the development of insulin resistance
since elevated ceramide levels have been shown in tissues of
insulin-resistant animals [56], in skeletal muscle of lipid infused
humans [57], and in skeletal muscle of obese insulin-resistant
Fig. 2. Schematic representation of the synthesis of DAG. Upper part of the figure
shows the synthesis ofDAG fromG3PorMAG. The lower part of the figure shows
the generation of DAG by enzymatic breakdown of TAG, phospholipids, or PC.
G3P, glycerol-3-phosphate; LPA, lysophosphatidic acid; PA, phosphatidic acid;
DAG, diacylglycerol; TAG, triacylglycerol; MAG, mono acylglycerol; GPAT,
glycerol-3-phosphate acyltransferase; LPAAT, lysophosphatidate acyltransferase;
PPH, phosphatidic acid phosphohydrolase; DGK, diacyl glycerolkinase; MGAT,
acyl-coA: monoacylglycerol acyltransferase; PLC, phospholipase; PLD, phos-
pholipase D; DGAT, diacylglycerol acyltransferase.
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hydrolysis of sphingomyelin, one of the four common phospho-
lipids found in the lipid bilayer of the cell, catalysed by the
enzyme sphingomyelinase [59], or via de novo synthesis from
saturated fatty acids [60]. Tumor necrosis factor α (TNFα) has
also been shown to stimulate sphingomyelinase and hence in-
crease ceramide levels [61]. This might be important since an
increased inflammatory state is also observed in obese individuals
[62]. Ceramides might mediate their antagonistic effect on insulin
signalling via inhibition of the phosphorylation of Akt [62,63],
independently of changes in the ability of insulin to stimulate IRS-
1 phosphorylation or PI3 kinase activation. Indeed, Hajduch et al.
[64] showed that incubation of L6 muscle cells with the short-
chain ceramide analogue C2-ceramide for 2 h resulted in a
complete loss of insulin-stimulated glucose transport and gly-
cogen synthesis, caused by a failure to activate Akt. Also in-
cubation of C2C12 muscle cells with the saturated fatty acid
palmitate leads to elevation of ceramide and inhibition of Akt and
thereby reducing insulin signalling [63]. Moreover, blocking
ceramide synthesis in palmitate-treated myotubes, restored Akt
activation by insulin [65]. Taken together, there is evidence for a
role of ceramides in the development of muscular insulin
resistance. However a precise understanding of the molecular
mechanism by which ceramides regulate insulin action is still
elusive [62]. For a more extensive review about the role of
ceramides in insulin resistance see Summers et al. [62].
4.3. DAG
DAG is another interesting candidate thatmight be responsible
for lipid-induced insulin resistance. DAG levels have been found
to be associated with insulin resistance after high-fat feeding in
rats, in obese Zucker (fa/fa) rats and in denervated soleus muscle
[66–71].
DAG can be derived from multiple sources (Fig. 2). First of
all, breakdown of phospholipids by the enzyme phospholipase C
(PLC) can generate DAG [72]. Secondly, DAG can be generated
from phospholipase D (PLD) -mediated hydrolysis of phospha-
tidylcholine (PC). However, in case of lipid-induced insulin
resistance a third principal source, the de novo synthesis of DAG
by esterification of two LCACoAs to glycerol-3-phosphate, is
probably themost important route. During the first acylation step
catalyzed by glycerol-3-phosphate acyltransferase (GPAT), a
fatty acyl-CoA is linked to the first (sn-1) position of the glycerol
molecule, giving rise to lysophosphatidic acid (LPA). The
second fatty acyl-CoA is attached to the second (sn-2) position
of the glycerol backbone by the enzyme lysophosphatidate
acyltransferase (LPAAT), forming a second precursor: phos-
phatidic acid (PA). The latter is subsequently transformed into
DAG through the action of phosphatidic acid phosphohydrolase
(PPH). TAG could then be formed by the action of diacylgly-
cerol acyltransferase (DGAT) [73]. Alternatively, hydrolysis of
TAG by the activity of lipases also results in increased DAG
levels. Until recently, hydrolysis of TAG was believed to occur
via hormone sensitive lipase (HSL). However, the observation
that HSL deficient mice accumulate DAG [74], was the first
indication that another myocellular lipase should be present forhydrolysis of IMTG. Recently, AdiposeTriGlycerideLipase
(ATGL) [75–77] was discovered and this enzyme is now
regarded as the main lipase responsible for hydrolysis of TAG to
DAG. Indeed overexpresssion of ATGL resulted in massive
increases in DAG levels [77] and might increase the risk to
develop insulin resistance.
DAG is thus important as an intermediate in TAGmetabolism,
and it also occupies a central position in the biosynthesis of
glycerophospholipids, which are the main components of cell
membranes [73]. Furthermore, DAG is an important second
messenger involved in intracellular signalling and thought to have
detrimental effects on insulin signalling through its ability to
activate PKC [14].
PKC is a family of structurally and functionally related
proteins derived from multiple genes after alternative splicing
[78,79]. PKC is activated in a response to a transient increase in
DAG or after the exposure to exogenous tumour-promoting
agents known as phorbol esters, which results in the translocation
of the protein from the cytosol to the plasmamembrane. A total of
12 isozymes of PKC have been cloned and characterized so far,
which are classified into three different subfamilies [80]. Each
isoform shows a different pattern of tissue distribution, substrate
specificity and cofactor requirement. The classical PKC isoforms
(cPKC α, βI, βII, γ) are calcium- and phospholipids-dependent
and are activated by phosphatidylserine (PS), calcium and DAG
(or phorbol ester). The novel PKCs (nPKC δ, ε, θ, η) are calcium-
independent but phospholipids-dependent; they require PS and
246 S. Timmers et al. / Physiology & Behavior 94 (2008) 242–251DAG for activation. The atypical PKC isoforms (aPKC ζ, ι/λ) are
calcium and phospholipid independent. Although the aPKCs are
dependent on the presence of PS for their catalytic activity, these
isoforms are not activated by calcium, DAG or phorbol esters.
During activation these kinases can translocate from the
cytosol to the cell membrane and the extent to which PKC is
found in membrane fractions is commonly used as a measure of
its activation. As a consequence of prolonged activation, PKC
can also be downregulated by proteolysis.
Activation of one or more PKC isoforms leads to a variety of
biological responses, including changes in cell proliferation and
differentiation, transmembrane ion transport, glucose and lipid
metabolism, smooth muscle contraction and gene expression
[81–83]. Very little is known about the functional specificity of
different PKC isoforms. Animal studies have mainly implicated
the nPKCs, PKCε, and PKCθ in muscle insulin resistance
[66,84,85] whereas activation of aPKCs can lead to insulin-
mediated GLUT4 translocation to the plasma membrane, which
enables glucose uptake in skeletal muscle [86].
Nowadays, DAG activation of the novel PKC isoforms
is considered as a major determinant of lipid-induced insulin
resistance.
One mechanism through which PKC could account for the
insulin signalling defect is phosphorylation of the IR. It seems
that serines on the β subunits of the IR kinase are an important
target for PKC phosphorylation [87]. Serine phosphorylation, in
stead of the normal insulin-stimulated tyrosine phosphorylation,
has been considered to be one of the mechanisms for inhibition
of IR function [88]. Specifically, the structural mechanism
appears to involve IRS protein dissociation from the insulin
receptor by inducing conformational changes, thereby impeding
access to tyrosine phosphorylation sites [89,90].
In the immediate downstream signalling events following IR
stimulation, PKCs also phosphorylate and modulate the IRS
proteins [91]. There are over 70 potential serine phosphorylation
sites on IRS-1, and in general, serine phosphorylation seems to
negatively regulate IRS signalling. Studies have demonstrated
hyper-serine phosphorylation of IRS-1 on ser302, ser307, ser612,
and ser632 in several insulin-resistant rodent models [92–95], as
well as in lean insulin-resistant offspring of type 2 diabetic parents
[96]. In vitro studies have shown that serine phosphorylation may
lead to dissociation between the IR/IRS-1 and/or IRS-1/PI3
kinase, preventing PI3 kinase activity [97–100]. Ultimately, this
IRS-1 inhibition will result in decreased insulin-stimulated
glucose transport (GLUT 4) activity and glucose uptake.
5. A link between DAG and insulin resistance
In rodents, a number of studies have provided evidence for
the association between aberrant activation of PKC and de-
creased insulin sensitivity, especially associated with increased
lipid loading in insulin-responsive tissues. Alterations in specific
isoforms of PKC were observed in skeletal muscle of high-fat
fed rats. An increase in the proportion of membrane-localized
PKCε, PKCθ and PKCδ, which correlated with IMTG and
DAG content was found in red skeletal muscle from high-fat fed
rats, suggesting chronic activation, while the diminished totalamounts of PKCθ and PKCδ also indicated proteolysis [66]. In
addition, a five-hour lipid infusion was also shown to increase
the translocation of PKCθ from the cytosol to the membrane in
skeletal muscle [85]. A study by Yu et al. [101] showed that
infusion of a lipid emulsion in rats resulted in a three-fold
increase in intracellular DAG mass, which was associated with
PKCθ activation. Coinciding with the increased PKCθ activity,
they observed a 30% reduction in insulin activation of IRS-1
tyrosine phosphorylation and approximately a 50% reduction in
IRS-1 associated PI3 kinase activity. PKC activity, DAG content
and PKCε and PKCθmembrane localization were also increased
in a study of obese Zucker rats [70]. Moreover, treatment of
high-fat fed rats with an antilipolytic drug rosiglitazone, which
reduced muscle DAG and IMTG levels, improved insulin
sensitivity and reversed the diet-induced changes in nPKC
expression [102]. Similarly, rapid reversal of insulin resistance
in high-fat fed rats by an acute dietary intervention with one
high-glucose low-fat meal also normalized PKCθ activation
[103]. Furthermore, PKCθ knockout mice are protected from
fat-induced insulin resistance in skeletal muscle. Kim et al. [92]
showed that in contrast to wild-type mice, PKCθ knockout mice
had no decreases in insulin-stimulated tyrosine phosphorylation
of IRS-1 and IRS-1-associated PI3 kinase activity after a five-
hour lipid infusion.
In humans, both PKCθ protein content and activity were
significantly increased in the rectus abdominus skeletal muscle
from obese diabetic subjects compared to skeletal muscle from
obese, normoglycemic controls, suggesting involvement of this
isoform in type 2 diabetes [104]. Recently, the same group has
shown that fatty acid induced muscle insulin resistance in normal
volunteers was found to be associated with increased DAG mass
and with PKC isoform β2 and θ membrane translocation [32].
Taken together, these studies strongly support a link between
IMTG, DAG accumulation, insulin resistance and activation of
PKC, although the relative roles of the different PKC isoforms
involved remain unclear.
6. Modulation of DAG
As reviewed above, substantial evidence links DAG ac-
cumulation, via activation of the nPKC isoforms, to the de-
velopment of muscular insulin resistance. This makes DAG
content an important target for therapeutic interventions.
As DAG is an intermediate in the synthesis of TAG from
glycerol and fatty acids, its levels can be lowered either by
improving the oxidation of cellular fatty acids by genetically
modifying carnitine palmitoyl transferase 1 (CPT1) [105], or by
accelerating the incorporation of fatty acids into TAG. The latter
can be achieved by genetically modifying enzymes that are
involved in the synthesis and hydrolysis of TAG, such as
diacylglycerol acyltransferase (DGAT), glycerol-3-phosphate
acyltransferase (GPAT), and stearoyl-CoA desaturase (SCD-1)
[106–108].
DGATcatalyzes the final step in TAG synthesis by facilitating
the linkage of sn-1,2-diacylglycerol with LCACoA. DGATexists
in two primary isoforms: DGAT1 andDGAT2 [108,109]. DGAT1
is ubiquitously expressed in human and mouse tissue, with the
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tissue [108] and it appears to have a role in fat absorption and
energy homeostasis [110]. DGAT2 is primarily expressed in liver
and white adipose tissue [109]. Revealing the function of DGAT2
has proven to be more difficult because homozygous DGAT2
knockout mice die shortly after birth due to severe lipopenia and
impaired skin barrier function [111].
Since DGAT1 is present in all insulin-sensitive tissues, ma-
nipulation of DGAT1 activity could be an attractive target for
manipulation of DAG content. It can be hypothesized that an
increase in DGAT1 activity would increase the conversion of
DAG into TAG, thereby lowering DAG content and improving
insulin sensitivity. Conversely, ablation of DGAT1 could be
expected to result in elevatedDAG levels. Consistentwith the role
of DGAT1, mice lacking DGAT1, showed 30–40% decreased
levels of TAG in adipose tissue and skeletal muscle [112]. In
accordance with the decrease in adiposity, DGAT1−/− mice
have an improved whole body insulin sensitivity as shown by
an increase in glucose infusion rate during hyperinsulinemic
euglycemic clamp studies [112]. Insulin-stimulated glucose
transport is increased in skeletal muscle and white adipose tissue
of DGAT1 deficient mice, and the insulin-stimulated activity of
keymolecules in the insulin signalling pathway, such as PI3K and
Akt is also increased in skeletalmuscle of thesemice [113]. Partial
deletion of DGAT1 also appeared to improve insulin sensitivity,
as evidenced by decreased blood glucose levels after intra-
peritoneal injections of insulin in inbred DGAT1-heterozygous
(DGAT1+/−) mice [114].
Although it is not surprising that the leanness in DGAT1
deficient mice leads to an improved insulin sensitivity, the precise
mechanisms that contribute to the insulin sensitivity remain
unresolved. It is hypothesized that DGAT1 deficiency in white
adipose tissue alters its endocrine function [112,115], thereby
promoting energy expenditure and sensitivity to insulin [116]. To
test this hypothesis, white adipose tissue was transplanted from
DGAT1 deficient mice into wild-type recipient mice and its
effects on glucose disposal and the response to a high-fat diet was
monitored. The recipient mice acquired partial obesity resistance,
increased insulin-stimulated glucose disposal, and enhanced
activation of the insulin signalling pathway [113,117]. These
results strongly suggest that the altered expression and secretion
of adipocyte-derived factors exert beneficial effects on energy and
glucose metabolism. It therefore is of considerable interest to
determine the adipocyte-derived factors that contribute to the
overall improved insulin sensitivity in DGAT1 deficient mice. It
appears that adipocytes that lack a functional DGAT1 enzyme
have an increased leptin sensitivity, and DGAT1 deficient mice
losemoreweight thanwild-typemice in response to subcutaneous
leptin infusion [112]. Furthermore, expression of adiponectin, a
white adipose tissue-derived hormone that improves insulin
sensitivity and increases fatty acid oxidation, is also increased in
DGAT1 deficient mice [118,119].
Although tissue TAG levels are reduced in DGAT deficient
mice, levels of DAG and fatty acyl-coA, substrates of the DGAT
reaction, are not elevated and even tended to be lower in skeletal
muscle and liver [112]. These findings disagreed with the
expectations that based on the function of DGAT1, DAG levelswould be increased, which would worsen the insulin sensitivity.
Yen et al. [120] proposed that the absence of muscle DAG
accumulation might be explained in part by the loss of acyl-
CoA: monoacylglycerol acyltransferase (MGAT) activity
mediated via DGAT1. This implies that DGAT1 could catalyze
the sequential esterification of two fatty acyl moieties to convert
monoacylglycerol to diacylglycerol and then to triacylglycerol.
In other words, fatty acid uptake might be altered in DGAT−/−
mice. If this is indeed a function of DGAT in intact cells still
requires further testing.
Contrary to the above mentioned findings, skeletal muscle-
specific transgenic overexpression of DGAT1 in mice protected
against fat-induced insulin resistance [121]. Myocellular over-
expression of DGAT1 resulted in decreased DAG and ceramide
levels and increased IMTG levels. The reduction in high-fat
diet-induced insulin resistance could in part be attributed to
attenuation of fat-induced activation of DAG-responsive PKCs.
The level of membrane-bound PKC activity of all the DAG-
responsive isoforms combined were lower in the high-fat fed
DGAToverexpressing mice than in high-fat fed wild-type mice,
but were comparable to the levels of normal chow-fed wild-type
mice. Measurement of DAG-sensitive PKC isoforms βII, ε, and
θ confirmed these results.
Moreover, a role for DGAT1 attenuating lipid-induced in-
sulin resistance was shown in isolated muscles from whole body
DGAT1 knockout mice, muscle-specific DGAT1 overexpres-
sing mice and wild-type mice, which were incubated with a
combination of palmitate and oleate [121]. Muscle from DGAT1
overexpressing mice showed enhanced insulin sensitivity
compared to muscle from wild-type mice, whereas DGAT1
deficiency was associated with diminished skeletal muscle in-
sulin sensitivity upon administration of fatty acids. The at-
tenuation of fatty acid-induced insulin resistance in DGAT
overexpressing mice was associated with decreased DAG and
ceramide levels comparable with levels observed in control
mice. In accordance, the decreased insulin sensitivity in soleus
muscle of DGAT1 deficient mice correlated with increased
accumulation of DAG mass and increased ceramide levels.
These results are in contrast with the earlier mentioned results of
Chen et al. [112], who showed decreased DAG levels in whole
body DGAT1 knockout mice, and an improved overall insulin
sensitivity, again suggesting that altered systemic factors (i.e.
circulating adipokines) in these mice may have affected the
phenotype observed in skeletal muscle [113].
Thus, it seems that the levels of DGAT1 in skeletal muscle
indeed determine muscle insulin sensitivity and susceptibility to
fatty acid-induced insulin resistance, as evidenced by decreased
DAG and ceramide levels.
Improving the oxidation capacity of muscle cells can also
modulate DAG levels. Indeed, Sebastiάn et al. [105] showed that
incubation of L6E9 muscle cells overexpressing CPT1 with
palmitate were protected against fatty acid-induced insulin
resistance by inhibiting both the accumulation of lipidmetabolites
such as DAG and ceramides, and the activation of PKCθ and
PKCζ. In the absence of palmitate incubation CPT1 overex-
pression affected neither basal nor insulin-stimulated glucose
metabolism. After a 16 h incubation with palmitate, insulin no
248 S. Timmers et al. / Physiology & Behavior 94 (2008) 242–251longer stimulated glucose uptake in control cells. This insensi-
tivity correlated with the accumulation of TAG, DAG and
ceramide. However, in CPT1 overexpressing cells insulin still
stimulated glucose uptake after palmitate treatment to the same
extent as in control cells without palmitate addition. This pro-
tection was associated with a reduction of palmitate incorporation
into cellular lipids, and reduced levels of DAG and ceramides.
Another way to manipulate DAG may be via acute exercise
and/or endurance training. Bruce et al. [41] showed that an 8week
endurance training program increased insulin sensitivity, accom-
panied by decreased levels of DAG. This decrease in DAG was
not accompanied by changes in IMTG content. Schenk and
Horowitz [122] tested the hypothesis that a single session of
exercise in human subjects would protect against fatty acid-
induced insulin resistance, when subjects received a 4 h lipid
infusion. It was shown that one single bout of exercise was
capable of markedly improving insulin sensitivity. This was
accompanied by an increase increased IMTG content, suggesting
that a single bout of exercise may reduce the storage of fatty acids
as metabolically unfavourable fatty acid metabolites. A possible
mechanism for increased IMTG storage after exercise was the
enhancement of the lipogenic capacity of skeletal muscle, as
evidenced by increased protein expression of mGPAT, DGAT1,
and SCD1. Ikeda et al. [123] also showed that a twoweek exercise
training in mice increased the gene expression of DGAT1.
Next to exercise and genetic manipulation of genes involved
in TAG metabolism, DAG may also be manipulated by dietary
fatty acid composition. Studies in lipid-pretreated cells have
shown that different types of fatty acids can lead to differences in
the content of fatty acid intermediates [124,125]. Chavez et al.
[124] showed that incubation of C2C12 myotubes with pal-
mitate, but not oleate, inhibited insulin-stimulated glycogen
synthesis accompanied by accumulation of DAG and ceramides.
Incubation with longer chain saturated fatty acids also reduced
insulin sensitivity and elevated DAG and ceramide levels,
whereas incubation with medium chain fatty acids had no effect
on insulin sensitivity or accumulation of DAG or ceramides.
Similar results were obtained by Montell et al. [125] and Gaster
et al. [126]. They showed that incubation of muscle cells with
palmitate increased the incorporation of fatty acids into DAG
whereas the unsaturated fatty acids were diverted towards
storage in the TAG pool or present in the FFA pool [125].
An explanation for the effect of fatty acid type on the conversion
towardsTAGmight be adifferent affinity ofDGAT1 for the saturated
versus the unsaturated fatty acids [125]. Coleman and Bell [127]
showed that DGAT, isolated from fat cells, had a maximal activity
when di-olein was used, whereas DGATactivity was minimal when
di-palmitin was used as a substrate. Likewise, in L6 myotubes,
DGAT also had a maximal activity for unsaturated acyl-CoAs,
compared with saturated acyl-CoAs [128]. Moreover, Montell et al.
[125] showed that increasing the concentration of oleate in a mixture
of palmitate and oleate progressively declined the incorporation of
palmitate into DAG, whereas the TAG concentration increased.
Taken together, these studies suggest that especially saturated
fatty acids lead to the accumulation of DAG in muscle cells,
whereas unsaturated fatty acids preferably stimulate the conversion
into TAG. In that context it is interesting to note that it has beenshown that diets high in saturated fatty acids are more prone to
result in insulin resistance compared to diets rich in unsaturated
fatty acids in humans [129].
However, the number of studies that have addressed the
effects of different fatty acid subtypes on insulin resistance in
vivo in humans and animals is scarce. A possible way to examine
this relationship is by means of the lipid infusion model. Studies
using lipid emulsions to increase plasma fatty acid levels and
muscular fatty acid intermediates in rats and humans showed an
increase in DAG associated with increased PKC activity and
decreased insulin sensitivity in rats and humans [32,101]. Both
studies only observed an increase in the level of muscular DAG
and not in intracellular ceramide or TAG concentrations, sug-
gesting that these metabolites do not play a major role in
mediating fatty acid-induced insulin resistance in skeletal
muscle. This model could also be used to examine the effect
of fatty acid subtype on lipid intermediate accumulation but until
now studies have almost exclusively used intralipid, which is
mainly composed of polyunsaturated fatty acids, as lipid
emulsion. Therefore, it would be very interesting to study the
effects of other lipid emulsions, with increased contribution of
saturated fatty acids, on DAG accumulation, DAG type, PKC
translocation and muscular insulin resistance.
7. Conclusion and future perspectives
In this review, we have summarized the effects of ectopic
lipid accumulation on skeletal muscle insulin resistance.
Among the many lipid metabolites that might contribute to
the onset of insulin resistance, DAG has attracted particular
interest. DAG is an intermediate in the synthesis of TAG from
FFA and numerous studies have shown an association between
DAG accumulation and the degree of insulin resistance.
If indeed the current sedentary life-style and the continuous
access to energy-rich food is associated with high DAG levels,
modulation of DAGmight be an important therapeutic strategy to
improve overall insulin sensitivity. It has been shown that DAG
can be decreased by physical activity. Furthermore, dietary fatty
acid composition has the potential to affect DAG content, al-
though a limited number of publications are available. Therefore,
more (human) research is needed to unravel the exact effect of
fatty acid composition on DAG levels and insulin resistance.
An area that so far has been hardly addressed is the role that
different subtypes of DAG may play in the development of
insulin resistance. It can be suggested that the effect of fatty acid
saturation and chain length on muscular insulin resistance as
observed in muscle cells is not only due to an effect on DAG
content, but also on DAG composition. So far, the analysis of
different DAG species and their effects on PKC activity or
translocation within the cell has been proven difficult, but is an
area that certainly deserves further investigation.
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